PT  - JOURNAL ARTICLE
AU  - Matt J. Keeling
AU  - Ellen Brooks-Pollock
AU  - Rob Challen
AU  - Leon Danon
AU  - Louise Dyson
AU  - Julia R. Gog
AU  - Laura Guzmán Rincón
AU  - Edward M. Hill
AU  - Lorenzo Pellis
AU  - Jonathan M. Read
AU  - Michael J. Tildesley
TI  - Short-term Projections based on Early Omicron Variant Dynamics in England
AID  - 10.1101/2021.12.30.21268307
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.30.21268307
4099  - http://medrxiv.org/content/early/2021/12/30/2021.12.30.21268307.short
4100  - http://medrxiv.org/content/early/2021/12/30/2021.12.30.21268307.full
AB  - Throughout the ongoing COVID-19 pandemic, the worldwide transmission and replication of SARS-COV-2, the causative agent of COVID-19 disease, has resulted in the opportunity for multiple mutations to occur that may alter the virus transmission characteristics, the effectiveness of vaccines and the severity of disease upon infection. The Omicron variant (B.1.1.529) was first reported to the WHO by South Africa on 24 November 2021 and was declared a variant of concern by the WHO on 26 November 2021. The variant was first detected in the UK on 27 November 2021 and has since been reported in a number of countries globally where it is frequently associated with rapid increase in cases. Here we present analyses of UK data showing the earliest signatures of the Omicron variant and mathematical modelling that uses the UK data to simulate the potential impact of this variant in the UK. In order to account for the uncertainty in transmission advantage, vaccine escape and severity at the time of writing, we carry out a sensitivity analysis to assess the impact of these variant characteristics on future risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMJK, EBP, LD, LD, JRG, LGR, LP, JMR and MJT were supported by UKRI through the JUNIPER modelling consortium [grant number MR/V038613/1]. MJK, EMH and MJT were supported by the Biotechnology and Biological Sciences Research Council [grant number: BB/S01750X/1]. MJK is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool in partnership with UK Health Security Agency (UKHSA), in collaboration with University of Warwick. MJK is also affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Genomics and Enabling Data at University of Warwick in partnership with UK Health Security Agency (UKHSA). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or UK Health Security Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data from the CHESS database were supplied after anonymisation under strict data protection protocols agreed between the University of Warwick and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M(O) / SAGE committees.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on reported cases, deaths and vaccination used in this model are at the individual level and therefore confidential, with public data deposition non-permissible for socioeconomic reasons. The ethics of the use of these data for these purposes was agreed by the UK Health Security Agency with the Governments SPI-M(O) / SAGE committees. More aggregate data is freely available from the UK Coronavirus dashboard: https://coronavirus.data.gov.uk/